Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study
Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study
About this item
Full title
Author / Creator
Annovazzi, Pietro , Capobianco, M. , Moiola, L. , Patti, F. , Frau, J. , Uccelli, A. , Centonze, D. , Perini, P. , Tortorella, C. , Prosperini, L. , Lus, G. , Fuiani, A. , Falcini, M. , Martinelli, V. , Comi, G. and Ghezzi, A.
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to e...
Alternative Titles
Full title
Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1827894621
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1827894621
Other Identifiers
ISSN
0340-5354
E-ISSN
1432-1459
DOI
10.1007/s00415-016-8188-y
